Multicentre analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No.9/GPOH and SIOP 93-01/GPOH

Med Pediatr Oncol. 2002 Jul;39(1):18-24. doi: 10.1002/mpo.10081.

Abstract

Background: To study cardiac function and the incidence of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No.9/GPOH and SIOP 93-01/GPOH.

Procedure: Analysis of clinical status, echocardiography, and ECG findings prior to administration of anthracyclines (median cumulative doxorubicin dose: 250 mg/m(2) [range: 90-411 mg/m(2)] and after a median posttherapeutic interval of 2.9 years [range: 0-10.2 years]. Data on cardiac function before and/or after therapy could be obtained of 186 patients.

Results: Posttherapy left ventricular fractional shortening was reduced in 4/157 (2.5%) patients. Out of the 4 children, 2 had clinically reduced tolerance to exercise and received anticongestive therapy. Abnormal ECG findings that were not detectable prior to therapy were found in 7/124 (5.6%) children.

Conclusions: The incidence of abnormal findings is low in our study group in comparison to data from the literature and might be due to the comparably short posttherapeutic interval.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Antibiotics, Antineoplastic / administration & dosage
  • Antibiotics, Antineoplastic / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Child
  • Child, Preschool
  • Dactinomycin / administration & dosage
  • Dactinomycin / adverse effects*
  • Echocardiography
  • Electrocardiography
  • Female
  • Germany / epidemiology
  • Heart Diseases / chemically induced
  • Humans
  • Infant
  • Kidney Neoplasms / drug therapy*
  • Male
  • Retrospective Studies
  • Surveys and Questionnaires
  • Time Factors
  • Ventricular Dysfunction, Left / chemically induced*
  • Ventricular Dysfunction, Left / diagnosis
  • Vincristine / administration & dosage
  • Vincristine / adverse effects*
  • Wilms Tumor / drug therapy*

Substances

  • Antibiotics, Antineoplastic
  • Dactinomycin
  • Vincristine

Supplementary concepts

  • SIOP protocol